Abstract:The ongoing COVID-19 pandemic caused by SARS-CoV-2 is a huge public health crisis for the globe. The receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein plays a vital role in viral infection and serves as a major target for developing neutralizing antibodies. In this study, the antibody response to the RBD of SARS-CoV-2 S protein was analyzed by a panel of sera from animals immunized with RBD-based antigens and four linear B-cell epitope peptides (R345, R405, R450 and R465) were revealed. The immunogenicity of three immunodominant peptides (R345, R405, R465) was further accessed by peptide immunization in mice, and all of them could induced potent antibody response to SARS-CoV-2 S protein, indicating that the three determinants in the RBD were immunogenic. We further generated and characterized monoclonal antibodies (15G9, 12C10 and 10D2) binding to these epitope peptides, and finely mapped the three immunodominant epitopes using the corresponding antibodies. Neutralization assays showed that all three monoclonal antibodies had neutralization activity. Results from IFA and western blotting showed that 12C10 was a cross-reactive antibody against both of SARS-CoV-2 and SARS-CoV. Results from conservative and structural analysis showed that 350 VYAWN 354 was a highly conserved epitope and exposed on the surface of SARS-CoV-2 S trimer, whereas 473 YQAGSTP 479 located in the receptor binding motif (RBM) was variable among different SARS-CoV-2 strains. 407 VRQIAP 412 was a highly conserved, but cryptic epitope shared between SARS-CoV-2 and SARS-CoV. These findings provide important information for understanding the humoral antibody response to the RBD of SARS-CoV-2 S protein and may facilitate further efforts to design SARS-CoV-2 vaccines and the target of COVID-19 diagnostic.

A core epitope targeting antibody of SARS-CoV-2

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD

A key linear epitope for a potent neutralizing antibody to SARS CoV 2 S RBD

The immunodominant and neutralization linear epitopes for SARS-CoV-2

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Analysis of the molecular mechanism of SARS-CoV-2 antibodies

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

A Potent Neutralizing Human Antibody Reveals the N-terminal Domain of the Spike Protein of SARS-CoV-2 As a Site of Vulnerability

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

Conserved Amino Acids W423 and N424 in Receptor-Binding Domain of SARS-CoV Are Potential Targets for Therapeutic Monoclonal Antibody.

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Uncovering a Conserved Vulnerability Site in SARS‐CoV‐2 by a Human Antibody

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Neutralization of SARS-CoV-2 Infection by Antibodies Targeting Diverse Epitopes